Triple Therapy in COPD: Can We Welcome the Reduction in Cardiovascular Risk and Mortality?

Paolo Solidoro; Carlo Albera; Fulvia Ribolla; Michela Bellocchia; Luisa Brussino; Filippo Patrucco

doi:10.3389/fmed.2022.816843

Triple Therapy in COPD: Can We Welcome the Reduction in Cardiovascular Risk and Mortality?

Front Med (Lausanne). 2022 Mar 23:9:816843. doi: 10.3389/fmed.2022.816843. eCollection 2022.

Authors

Paolo Solidoro^{1

2}, Carlo Albera^{1

2}, Fulvia Ribolla¹, Michela Bellocchia¹, Luisa Brussino^{2

3}, Filippo Patrucco^{4

5}

Affiliations

¹ Division of University Respiratory Medicine, Cardiovascular and Thoracic Department, AOU Città della Salute e della Scienza di Torino, Turin, Italy.
² Department of Medical Sciences, University of Turin, Turin, Italy.
³ Allergy and Clinical Immunology Unit, AO Ordine Mauriziano Hospital, Turin, Italy.
⁴ Division of Respiratory Diseases, Medical and Specialistic Department, AOU Maggiore della Carità, Novara, Italy.
⁵ Translational Medicine Department, University of Piemonte Orientale, Novara, Italy.

Abstract

Chronic obstructive pulmonary disease (COPD) is a complex disease which consists in the reduction of the airflow and leads to the disruption of the pulmonary tissue due to a chronic inflammation. The progression of the disease is characterized by an exacerbation of the symptoms and the presence of life-threatening systemic complications, such as stroke and ischemic heart disease, with a progressive decline in lung function which can deeply impact the quality of life. Mortality represents the most important COPD outcome, with an increased risk in patients with cardiovascular comorbidities. The efficacy and safety of triple inhaled therapy were demonstrated by numerous controlled trials. Above all, many robust data are now available on the effectiveness of the triple therapy to reduce mortality in COPD patients.

Keywords: CV mortality; ICS; LABA; LAMA; chronic obstructive pulmonary disease (COPD); triple inhaled therapy.

Publication types

Review